centerforbiosimilars46m
Eye on Pharma: Korean Drugmakers’ Impact in Europe; New Denosumab, Eculizumab Deals
Korean drugmakers hold over 50% market share in the 6 best-selling biosimilar markets, 2 companies sign exclusive licensing ...
Samsung Bioepis, Teva Enter License, Development, Commercialization Agreement For EPYSQLI
Samsung Bioepis Co. and Teva Pharmaceutical Industries (TEVA have entered into a license, development and commercialization agreement ...
Teva, Samsung Bioepis enter partnership for commercialization of EPYSQLI
Pharmaceutical Industries announced that the companies have entered into a license, development and commercialization agreement for EPYSQLI, Samsung Bioepis’ biosimilar to Soliris in the United States ...
Le Lézard23h
The New Era of CDx in Oncology: Adapting Clinical Research Strategy to Evolving Regulations, Upcoming Webinar Hosted by Xtalks
For more information, or to register for this event, visit The New Era of CDx in Oncology: Adapting Clinical Research Strategy to Evolving Regulations.
Samsung Bioepis and Teva Enter into a Strategic Partnership for Commercialization of EPYSQLI® (eculizumab-aagh) in the United States
Marks a step forward in broadening treatment options for patients with paroxysmal nocturnal hemoglobinuria (PNH), atypical ...